Overview: NGS Corneal Dystrophy Sequencing TestIntroduction: The NGS Corneal Dystrophy Sequencing Test sequences genes to diagnose corneal dystrophy, causing vision loss or eye pain. Following 2023 AAO guidelines, it uses PCR for high specificity, supporting vision screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected corneal dystrophy.
Other Names: Corneal Dystrophy Assay, TGFBI Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Corneal dystrophy sequencing began in the 1990s with corneal disorder research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose corneal dystrophy, guides treatment, and evaluates patients with vision loss or eye pain.
Test Parameters: 1. Corneal Dystrophy Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of vision loss, eye pain, or corneal symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document vision loss, eye pain, photophobia, or family history of corneal dystrophy. Include current medications, especially eye drops.
Consent: Written consent required, detailing the tests purpose, corneal dystrophy implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze corneal dystrophy genes (e.g., TGFBI). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for corneal dystrophy diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm corneal dystrophy, guiding surgical intervention or genetic counseling. Negative results may require corneal imaging.
Specialist Consultation: Consult an ophthalmologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Corneal topography, slit-lamp examination, or pachymetry to confirm corneal dystrophy diagnosis.
Test Limitations: Not all corneal dystrophies are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAO Corneal Dystrophy Guidelines, 2023; Ophthalmology, Weiss JS, 2022.
